[Inhibition of angiogenesis in the anterior chamber of the eye].
BACKGROUND
Recent years have seen tremendous progress in our understanding of the mechanisms of neovascular diseases of the eye. Antiangiogenic treatment options are now widely used in the management of age-related maculopathy (AMD) and diabetic retinopathy. The aim of this article is to highlight some novel methods of local antiangiogenic treatment of the cornea and conjunctiva and in the anterior chamber of the eye.


METHODS
The study took the form of a literature review (PUBMED) and a review of the authors' own data.


RESULTS
Initial experience with novel inhibitors of angiogenesis, especially bevacizumab, used locally on cornea and conjunctiva is promising. Intracameral injections of VEGF inhibitors can be used to ameliorate neovascular glaucoma.


CONCLUSIONS
Novel antiangiogenic drugs are available for topical use in the anterior segment of the eye (as off-label use) and will improve the management of neovascular diseases affecting cornea and conjunctiva and in the anterior chamber of the eye.
Bock
F
F
Augenklinik mit Poliklinik, Friedrich-Alexander-Universität Erlangen Nürnberg, Erlangen, Deutschland.
König
Y
Y
Dietrich
T
T
Zimmermann
P
P
Baier
M
M
Cursiefen
C
C
D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D016510:Corneal Neovascularization / Q000188:drug therapy*; D006801:Humans; D017410:Practice Guidelines as Topic; D010818:Practice Patterns, Physicians' / Q000639:trends; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000008:administration & dosage*
D020533:Angiogenesis Inhibitors; D042461:Vascular Endothelial Growth Factor A